Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label TAK-853 in Japanese patients with FRα-positive advanced ovarian cancer and other solid tumors
jRCT2031240057Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- May 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of mirvetuximab soravtansine in ovarian cancer, endometrial cancer (EC), non-small cell lung cancer (NSCLC) and 7 more (2 arms), sponsored by Takeda. Primary endpoints: Number of participants with dose-limiting toxicities in Cycle 1, Number of participants with treatment-emergent adverse events and 8 more. Started May 2024; status: active, not recruiting.
02
Drugs
mirvetuximab soravtansine
03
Conditions
ovarian cancerendometrial cancer (EC)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on jRCT2031240057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240057.